Peichao Li

Peichao Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2024 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
LLLing-Bing Li
Ling-Bing Li
LYLing-Xiao Yang
Ling-Xiao Yang
LLLei Liu
Lei Liu
FLFan-Rong Liu
Fan-Rong Liu
ALAlex H. Li
Alex H. Li
XZXiao-Gang Zhao
Xiao-Gang Zhao
Paclitaxel resistance is associated with a poor prognosis in non-small cell lung cancer (NSCLC) patients, and currently, there is no promising drug for paclitaxel resistance. In this study, we investigated the molecular mechanisms underlying the chemoresistance in human NSCLC-derived cell lines. We constructed paclitaxel-resistant NSCLC cell lines (A549/PR and H460/PR) by long-term exposure to paclitaxel. We found that triptolide, a diterpenoid epoxide isolated from the Chinese medicinal herb Tripterygium wilfordii Hook F, effectively enhanced the sensitivity of paclitaxel-resistant cells to paclitaxel by reducing ABCB1 expression in vivo and in vitro. Through high-throughput sequencing, we identified the SHH-initiated Hedgehog signaling pathway playing an important role in this process. We demonstrated that triptolide directly bound to HNF1A, one of the transcription factors of SHH, and inhibited HNF1A/SHH expression, ensuing in attenuation of Hedgehog signaling. In NSCLC tumor tissue microarrays and cancer network databases, we found a positive correlation between HNF1A and SHH expression. Our results illuminate a novel molecular mechanism through which triptolide targets and inhibits HNF1A, thereby impeding the activation of the Hedgehog signaling pathway and reducing the expression of ABCB1. This study suggests the potential clinical application of triptolide and provides promising prospects in targeting the HNF1A/SHH pathway as a therapeutic strategy for NSCLC patients with paclitaxel resistance.

5 February 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
PLPeichao Li
Peichao Li
LYLingxiao Yang
Lingxiao Yang
SPSun Young Park
Sun Young Park
FLFanrong Liu
Fanrong Liu
ALAlex H. Li
Alex H. Li
XZXiao-Gang Zhao
Xiao-Gang Zhao

21 June 2024 in Oncogenesis
Verified
Journal Article
Open access
PDF file
JGJiazhong Guo
Jiazhong Guo
YZYunpeng Zhao
Yunpeng Zhao
HSHuacong Sui
Huacong Sui
LLLei Liu
Lei Liu
FLFanrong Liu
Fanrong Liu
XZXiao-Gang Zhao
Xiao-Gang Zhao
Lacking effective therapeutic targets heavily restricts the improvement of clinical prognosis for patients diagnosed with esophageal squamous cell carcinoma (ESCC). Ubiquitin Specific Peptidase 21 (USP21) is dysregulated in plenty of human cancers, however, its potential function and relevant molecular mechanisms in ESCC malignant progression as well as its value in clinical translation remain largely unknown. Here, in vitro and in vivo experiments revealed that aberrant upregulation of USP21 accelerated the proliferation and metastasis of ESCC in a deubiquitinase-dependent manner. Mechanistically, we found that USP21 binds to, deubiquitinates, and stabilizes the G3BP Stress Granule Assembly Factor 1 (G3BP1) protein, which is required for USP21-mediated ESCC progression. Further molecular studies demonstrated that the USP21/G3BP1 axis played a tumor-promoting role in ESCC progression by activating the Wnt/β-Catenin signaling pathway. Additionally, disulfiram (DSF), an inhibitor against USP21 deubiquitylation activity, markedly abolished the USP21-mediated stability of G3BP1 protein and significantly displayed an anti-tumor effect on USP21-driving ESCC progression. Finally, the regulatory axis of USP21/G3BP1 was demonstrated to be aberrantly activated in ESCC tumor tissues and closely associated with advanced clinical stages and unfavorable prognoses, which provides a promising therapeutic strategy targeting USP21/G3BP1 axis for ESCC patients.

24 December 2024 in Cancer Letters
Verified
Journal Article
Closed access
LYLingxiao Yang
Lingxiao Yang
HSHuacong Sui
Huacong Sui
YDYi Ding
Yi Ding
YZYilin Zhu
Yilin Zhu
XSXiangqing Song
Xiangqing Song
XZXiao-Gang Zhao
Xiao-Gang Zhao

21 October 2024 in Journal of Zhejiang University-SCIENCE B
Verified
Journal Article
Closed access
PDF file
YZYilin Zhu
Yilin Zhu
FLFanrong Liu
Fanrong Liu
LLLei Liu
Lei Liu
JWJinfu Wang
Jinfu Wang
FGFengyuan Gao
Fengyuan Gao
PLPeichao Li
Peichao Li
Hexavalent chromium Cr(VI), as a well-established carcinogen, contributes to tumorigenesis for many human cancers, especially respiratory and digestive tum

18 December 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
NMNing Mu
Ning Mu
FLFanrong Liu
Fanrong Liu
XSXiangqing Song
Xiangqing Song
BWBiao Wang
Biao Wang
YZYilin Zhu
Yilin Zhu
XZXiao-Gang Zhao
Xiao-Gang Zhao
Sonic Hedgehog signaling is aberrantly activated in non-small cell lung cancer (NSCLC). However, the regulatory molecules of Sonic Hedgehog signaling during NSCLC development are still largely unknown. Here, we demonstrated that HHIP Like 2 (HHIPL2) is a crucial Sonic Hedgehog signaling regulator, accelerating NSCLC progression via positively governing Sonic Hedgehog signaling. Clinically, HHIPL2 is highly expressed in NSCLC and indicates a poor prognosis. Consistently, via depletion or gain of HHIPL2 in vivo and in vitro, we identified its oncogenic role in NSCLC proliferation and metastasis. Mechanistically, HHIPL2 interacted with the RNA-binding protein HNRNPC to alter its nucleo-cytoplasmic translocation. HHIPL2-regulated HNRNPC accumulation in the cytoplasm promoted the mRNA stability of HNF1A, a transcription factor for SHH, which subsequently enhanced the Sonic Hedgehog signaling activity to facilitate NSCLC progression. Furthermore, we discovered that triptolide (TPL), an HNF1A inhibitor, impeded HHIPL2-mediated Sonic Hedgehog signaling activation and NSCLC malignancy. Therefore, our findings not only uncover a previously unrecognized role for HHIPL2 in regulating the Sonic Hedgehog signaling pathway but also highlight a novel HHIPL2/HNRNPC/HNF1A axis as an attractive target for NSCLC therapy.